Tobias Wertheimer
@WertheimerT
Physician scientist/ group leader hematology/oncology, cancer immunotherapy
🧬 We are hiring a PhD student for our Computational Oncology lab at @Uniklinik_Fr. You will use cutting-edge spatial technologies to decipher the cancer ecosystem in space and time. Please apply through: uniklinik-freiburg.de/medizin1/forsc…
Check out our new review article on spatially resolved single cell technologies and generative modeling and their application in immunology research. Fun collaboration with Avital, Hosna, @YosefLab, @IdoAmitLab and @FlorianIngelfi1 onlinelibrary.wiley.com/doi/10.1002/ej…
Are you an immunologist interested in spatially-resolved single cell technologies and generative modeling but dont know where to start? Check out our @EurJImmunol review with Avital, Hosna, Robert Zeiser, @IdoAmitLab, @YosefLab & @WertheimerT onlinelibrary.wiley.com/doi/10.1002/ej…
Online now: Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damage dlvr.it/THhzHQ
Free scientific illustrations for biologists! 😍 @NIH has released a library of 500+ free scientific illustrations to create figures, presentations, and illustrations! all freely available in the public domain. Retweet and spread the message! bioart.niaid.nih.gov
🧬 We are hiring a PhD student for our lab at @DKFZ and @KiTZ_HD! This is an exciting collaboration project with my former @marsonlab colleague @ShifrutLab - and of course it involves cutting-edge CRISPR technologies in human T cells.. Please apply through jobs.dkfz.de/en/jobs/167042…
Is personalized therapy for #leukemia relapse after stem cell transplant possible? jci.org/articles/view/… @NanaTalvard @ScienceLukas @vangalenlab @WertheimerT @KuchrooLab and team show anti-TIM-3 Ab improves survival of mice with mutation-specific leukemia.
If you’re excited about working at the intersection between wet and dry lab to better understand relapse after allo-HCT, consider joining our group for a PhD 😊 uniklinik-freiburg.de/karriere/stell…
We are hiring a software engineer! An amazing opportunity to join our team - be at the core of the development and maintenance of our open-source Python packages, engage with the single-cell omics community within the @scverse_team consortium and beyond! linkedin.com/jobs/view/3869…
Very excited to share our work on IL-23 and it’s role on Tregs in the TME now out @NatImmunol. A great team effort with @PascaleZwicky @BecherLab and @TuguesLab and many more. Very grateful to everyone who made this possible!!!
Our new lab vandenbrinklab.org at City of Hope is looking for energetic and enthusiastic #postdocs. If you are interested, please write to [email protected] 📧. #postdocposition #academicjobs #researchjobs #sciencejobs
Excited to share our work on Tregs in the TME at this fantastic conference #CICON23! @BecherLab @TuguesLab @PascaleZwicky @AACR @ENCI_network @CancerResearch
Excited to kick off the science debates on how to overcome resistance in #Immunotherapy today at #CICON23 hosted by @CancerResearch @ENCI_network and @AACR. 🧪 Let's connect! 🔬
📣 Code for SCimilarity is now available! Adapt our demos to your own queries and find similar cells across our 22.7M cell reference in seconds. github.com/Genentech/scim… 🧑💻
Ever analyze a scRNAseq dataset and wonder if a specific cell state has been seen before? And if so, where in the human body? Under what conditions? Well, now you can use our lightning fast SCimilarity search and foundational model for that! ⚡️🔎🧬 biorxiv.org/content/10.110… (1/11)
Ever wondered what the equivalent of differential gene expression is for cell-cell communication ? Look no further...it's MultiNicheNet, the first statistically sound framework for multi-sample multi-condition comparison of intercellular communication 👉doi.org/10.1101/2023.0…
In the latest issue! Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes dlvr.it/Sl6Vzv
Agonist #immunotherapy with engineered IL-18 following allogeneic bone marrow transplant in mice improved anti-tumor activity without increasing the chance of graft-versus-host onset. @fredhutch @MonashUni @simone_minnie @Geoff_Hill_Lab scim.ag/bY
After seeing vorinostat, panobinostat, elotuzumab, belantamab, venetoclax, melflufen, selinexor, ixazomib falter in myeloma, my thoughts on cancer drug development for investigators and Pharma. Simple. But simple is hard. 1/ #MedTwitter
Poster session with a view @MimZurich retreat. Thanks for the invitation. Great to be part of this!
